Skip to main content

Table 3 Antipsychotic polypharmacy combinations by treatment family in patients diagnosed with schizophrenia: 2008–2015

From: Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain

Polypharmacy combinations N (% of total) Subjects % Time %
OA-2nd generation 18,241 (27.5) 38.1 16.2
OA-2nd generation + LAI-2nd generation 16,188 (24.4) 26.0 12.7
OA-1st generation + OA-2nd generation 10,271 (15.5) 21.1 7.9
OA-1st generation + OA-2nd generation + LAI-2nd generation 4213 (6.3) 7.5 2.4
Othera + OA-2nd generation 3899 (5.9) 7.9 3.1
LAI-1st generation + OA-2nd generation 3325 (5.0) 7.6 3.1
Other combinations 10,281 (15.5) 31.8 6.3
  1. Abbreviations: OA Oral antipsychotic, LAI Long-acting injection antipsychotics
  2. aOther family treatments different to OA and LAI
  3. Subjects (%), percentage of subjects ever treated with each polypharmacy combination during the study period
  4. Time (%) represents the percentage of time, of the total study period, during which each combination has been used
  5. For each family, two or more concomitant treatments can be included